Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis |
| Type de publication | Journal Article |
| Year of Publication | 2021 |
| Auteurs | Samson M, Greigert H, Ciudad M, Gerard C, Ghesquiere T, Trad M, Corbera-Bellalta M, Genet C, Ouandji S, Cladiere C, Thebault M, Ly KHeang, Liozon E, Maurier F, Bienvenu B, Terrier B, Guillevin L, Charles P, Quipourt V, Devilliers H, Gabrielle P-H, Creuzot-Garcher C, Tarris G, Martin L, Saas P, Audia S, Cid MCinta, Bonnotte B |
| Journal | CLINICAL & TRANSLATIONAL IMMUNOLOGY |
| Volume | 10 |
| Pagination | e1332 |
| Type of Article | Article |
| Mots-clés | Giant Cell Arteritis, Interleukin-6, tocilizumab, Treg |
| Résumé | {Objectives. To study the percentage, suppressive function and plasticity of Treg in giant cell arteritis (GCA), and the effects of glucocorticoids and tocilizumab. Methods. Blood samples were obtained from 40 controls and 43 GCA patients at baseline and after treatment with glucocorticoids + IV tocilizumab (n = 20) or glucocorticoids (n = 23). Treg percentage and phenotype were assessed by flow cytometry. Suppressive function of Treg was assessed by measuring their ability to inhibit effector T-cell (Teff) proliferation and polarisation into Th1 and Th17 cells. Results. Treg (CD4(+)CD25(high)FoxP3(+)) frequency in total CD4(+) T cells was decreased in active GCA patients when compared to controls (2.5% vs. 4.7%, P < 0.001) and increased after treatment with tocilizumab but worsened after treatment with glucocorticoids alone. Treg lacking exon 2 of FoxP3 were increased in GCA patients when compared to controls (23% vs. 10% of total Treg |
| DOI | 10.1002/cti2.1332 |